NanoVibronix Announces Publication of Compelling Study Results for UroShield in The Journal of Medical & Surgical Urology
July 22 2021 - 8:15AM
NanoVibronix, Inc.,
(NASDAQ: NAOV), a medical device
company that produces the UroShield® and PainShield® Surface
Acoustic Wave (“SAW”) Portable Ultrasonic Therapeutic Devices,
today announced that The Journal of Medical & Surgical Urology
is publishing an article with overwhelmingly positive findings from
a study of patients that used its UroShield in real world
settings.
“This independent study is further proof of the
effectiveness and applicability of our UroShield device in reducing
the incidence of urinary tract infections and the pain and
discomfort caused by urinary catheters,” stated Brian Murphy, Chief
Executive Officer of NanoVibronix, Inc. “As we would expect, the
patient experiences in the study were statistically significant,
with all responding patients reporting that our device was simple,
easy to use and materially benefitted them. The patient experiences
were so profoundly positive that 100% of the study’s participants
are continuing to use the device following the conclusion of the
study.”
Murphy added, “Importantly, the study was conducted in
real world settings, including private residences and long-term
care facilities. Study participants, who often relied on family
members and other assistants, achieved positive outcomes without
the benefit of trained clinicians and skilled care givers,
reinforcing our assertion of the ease of use of the UroShield
device.”
For the study, 23 patients with reoccurring UTIs were
offered to use UroShield for a minimum period of 12 weeks.
Objective and subjective measures of improvement were recorded
every week, including the number of UTIs, antibiotic treatment,
catheter blockage and changes, bladder washout, hospitalizations or
nurse visits due to UTIs, level of pain, sleep and mobility. In the
findings, patients reported a significant decrease in the number of
UTIs and antibiotic treatment, had fewer catheter blockages and
catheter changes and pain was reduced significantly by the end of
the study.
Researchers at Coventry University concluded that
‘UroShield reduced the number of UTIs, catheter blockages and
changes, and consequently the need for antibiotics. Patients
reported the device is easy to use, were related to little to no
pain, and overall improved patients’ well-being and mobility.’ The
researchers suggest that the device should be considered as an
appropriate treatment in long-term persistent UTIs.
The peer reviewed publication has been submitted
to the National Institute for Clinical Excellence (NICE) as further
clinical evidence towards UroShield achieving NICE
Guidance.
A link to the complete article will be made available on
the company’s website at: nanovibronix.com.
About NanoVibronix, Inc.
NanoVibronix, Inc. (NASDAQ: NAOV) is a medical device
company headquartered in Elmsford, New York, with research and
development in Nesher, Israel, focused on developing medical
devices utilizing its patented low intensity surface acoustic wave
(SAW) technology. The proprietary technology allows for the
creation of low-frequency ultrasound waves that can be utilized for
a variety of medical applications, including for disruption of
biofilms and bacterial colonization, as well as for pain relief.
The devices can be administered at home without the assistance of
medical professionals. The Company’s primary products include
PainShield® and UroShield®, which are portable devices suitable for
administration at home without assistance of medical professionals.
Additional information about NanoVibronix is available at:
www.nanovibronix.com.
Forward-looking Statements
This press release contains “forward-looking
statements.” Such statements may be preceded by the words
“intends,” “may,” “will,” “plans,” “expects,” “anticipates,”
“projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,”
“potential” or similar words. Forward-looking statements are not
guarantees of future performance, are based on certain assumptions
and are subject to various known and unknown risks and
uncertainties, many of which are beyond the Company’s control, and
cannot be predicted or quantified, and include, among others,
statements regarding the completion of the public offering, the
satisfaction of customary closing conditions related to the public
offering and the intended use of net proceeds from the public
offering; consequently, actual results may differ materially from
those expressed or implied by such forward-looking statements. Such
risks and uncertainties include, without limitation, risks and
uncertainties associated with: (i) the geographic, social and
economic impact of COVID-19 on the Company’s ability to conduct its
business and raise capital in the future when needed, (ii) market
acceptance of our existing and new products or lengthy product
delays in key markets; (iii) negative or unreliable clinical trial
results; (iv) inability to secure regulatory approvals for the sale
of our products; (v) intense competition in the medical device
industry from much larger, multinational companies,; (vi) product
liability claims; (vii) product malfunctions; (viii) our limited
manufacturing capabilities and reliance on subcontractor
assistance; (ix) insufficient or inadequate reimbursements by
governmental and/or other third party payers for our products; (x)
our ability to successfully obtain and maintain intellectual
property protection covering our products; (xi) legislative or
regulatory reform impacting the healthcare system in the U.S. or in
foreign jurisdictions; (xii) our reliance on single suppliers for
certain product components, (xiii) the need to raise additional
capital to meet our future business requirements and obligations,
given the fact that such capital may not be available, or may be
costly, dilutive or difficult to obtain; (xiv) our conducting
business in foreign jurisdictions exposing us to additional
challenges, such as, e.g., foreign currency exchange rate
fluctuations, logistical and communications challenges, the burden
and cost of compliance with foreign laws, and political and/or
economic instabilities in specific jurisdictions; and (xv) market
and other conditions. More detailed information about the Company
and the risk factors that may affect the realization of forward
looking statements is set forth in the Company’s filings with the
Securities and Exchange Commission (SEC), including the Company’s
Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q.
Investors and security holders are urged to read these documents
free of charge on the SEC’s web site at: http://www.sec.gov. The
Company assumes no obligation to publicly update or revise its
forward-looking statements as a result of new information, future
events, or otherwise, except as required by law.
Brian Murphy
NanoVibronix, Inc.
630-338-5022
bmurphy@nanovibronix.com
Brett Maas
Hayden IR, LLC
646-536-7331
brett@haydenir.com
NanoVibronix (NASDAQ:NAOV)
Historical Stock Chart
From May 2024 to Jun 2024
NanoVibronix (NASDAQ:NAOV)
Historical Stock Chart
From Jun 2023 to Jun 2024